Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diet and exercise may boost quality of life for incurable cancer patients

NCT ID NCT06138223

Symptom relief Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a program of exercise and dietary changes can improve or maintain quality of life for people with incurable stomach or esophageal cancer. Researchers will compare two groups of about 196 patients: one group receives standard care, and the other adds a supervised exercise and nutrition plan. The main goal is to see if the extra support helps patients feel better physically and emotionally during their treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 196 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Incurable adenocarcinoma of the esophagus or stomach * Recurrence after treatment with curative intent or irresectable/metastatic disease at primary diagnosis. Inclusion can take place regardless of the plan or the actual initiation of multi-line systemic treatment. (i.e. patients that have already started with anticancer therapy are eligible for inclusion too)\* * Able and willing to perform the exercise and nutritional program and wear the activity tracker. * Able and willing to fill out the POCOP/RADICES questionnaires. * Life expectancy \> 12 weeks. * Age ≥ 18 years. Exclusion Criteria: * Unstable bone metastases inducing skeletal fragility as determined by the treating clinician. * Untreated symptomatic known brain metastasis. * Serious active infection. * Too physically active (i.e. \>210 minutes/week of moderate-to-vigorous intentional exercise) or engaging in intense exercise training comparable to the RADICES exercise program. * Severe neurologic or cardiac impairment according to the American College of Sports Medicine criteria. * Uncontrolled severe respiratory insufficiency as determined by the treating clinician or if the patient is dependent on oxygen suppletion in rest or during exercise. * Uncontrolled severe pain. * Any other contraindications for exercise as determined by the treating physician. * Any circumstances that would impede adherence to study requirements or ability to give informed consent, as determined by the treating clinician. * Pregnancy. * Note: After one year of recruitment we broadened our inclusion criteria from GAC patients receiving beyond first-line palliative treatment or best supportive care to any patient with recurrence/progression of GAC after curative treatment or irresectable/metastatic disease at diagnosis, regardless of timing or type of palliative treatment and number of lines received. This was done to increase generalizability and offer the intervention earlier in the palliative phase to enhance its benefits. We acknowledge this results in a more heterogeneous group, but we believe also a more representative group. The inclusion criterium before broadening was: Progressive disease after first-line palliative systemic treatment OR within 6 months after completion of curative treatment (i.e. within six months after neoadjuvant chemoradiation, adjuvant nivolumab, or definitive chemoradiation for esophageal adenocarcinoma or within six months after adjuvant 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) for gastric/esophageal cancer or neoadjuvant FLOT if no adjuvant FLOT was given, or after progression during participation in the LyRICX study). Patients on capecitabine monotherapy who are eligible for oxaliplatin reintroduction can be included, too.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroesophageal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal adenocarcinoma gastroesophageal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastroesophageal cancer Incurable disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC

    RECRUITING

    Amsterdam, North Holland, 1081HV, Netherlands

  • Beatrix Hospital

    RECRUITING

    Gorinchem, Netherlands

  • Bravis Ziekenhuis

    RECRUITING

    Roosendaal, Netherlands

  • Canisius Wilhelmina Ziekenhuis

    RECRUITING

    Nijmegen, Netherlands

  • Catharina Ziekenhuis

    RECRUITING

    Eindhoven, Netherlands

  • Diakonessenhuis

    NOT_YET_RECRUITING

    Utrecht, Netherlands

  • Elisabeth Tweesteden Hospital

    RECRUITING

    Tilburg, Netherlands

  • Erasmus Medical Center

    RECRUITING

    Rotterdam, Netherlands

  • Flevoziekenhuis

    RECRUITING

    Almere Stad, Netherlands

  • Frisius Medical Center

    RECRUITING

    Leeuwarden, Netherlands

  • HagaZiekenhuis

    RECRUITING

    The Hague, Netherlands

  • Ikazia Ziekenhuis

    RECRUITING

    Rotterdam, Netherlands

  • Jeroen Bosch Hospital

    ACTIVE_NOT_RECRUITING

    's-Hertogenbosch, Netherlands

  • Laurentius Ziekenhuis

    RECRUITING

    Roermond, Netherlands

  • Leiden Universitair Medisch Centrum

    RECRUITING

    Leiden, Netherlands

  • Meander Medical Center

    NOT_YET_RECRUITING

    Amersfoort, Netherlands

  • RadboudUMC

    RECRUITING

    Nijmegen, Netherlands

  • Reinier de Graaf

    RECRUITING

    Delft, Netherlands

  • Sint Antonius Hospital

    NOT_YET_RECRUITING

    Nieuwegein, Netherlands

  • Spaarne Gasthuis

    RECRUITING

    Hoofddorp, Netherlands

  • UMC Utrecht

    RECRUITING

    Utrecht, Utrecht, 3508GA, Netherlands

  • Zaans Medical Center

    RECRUITING

    Zaandam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.